Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 100,000 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the transaction, the chief executive officer owned 660,482 shares of the company’s stock, valued at approximately $58,895,179.94. The trade was a 13.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, October 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $60.99, for a total value of $1,829,700.00.
• On Tuesday, September 16th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00.

Kymera Therapeutics Stock Up 41.5%

NASDAQ KYMR traded up $27.68 during trading on Monday, hitting $94.30. 7,492,731 shares of the stock traded hands, compared to its average volume of 772,142. The company has a market capitalization of $6.78 billion, a P/E ratio of -26.27 and a beta of 2.28. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $103.00. The firm has a 50-day simple moving average of $61.48 and a 200-day simple moving average of $50.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The firm had revenue of $2.76 million for the quarter, compared to the consensus estimate of $23.15 million. As a group, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its holdings in shares of Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after buying an additional 540 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares during the period. Finally, Bessemer Group Inc. lifted its stake in Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after acquiring an additional 815 shares during the period.

Analysts Set New Price Targets

KYMR has been the subject of a number of recent research reports. Stifel Nicolaus set a $114.00 price objective on shares of Kymera Therapeutics in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Wednesday, October 8th. BTIG Research set a $138.00 price target on Kymera Therapeutics in a research report on Monday. Jefferies Financial Group reissued a “buy” rating and set a $73.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, November 4th. Finally, Mizuho initiated coverage on Kymera Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $81.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $81.68.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.